Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rifapentine + isoniazid + vitamin b6
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination regimen used for treating latent tuberculosis infection (LTBI). The 3HP regimen consists of 12 once-weekly doses of rifapentine and isoniazid with vitamin B6 over 3 months, while the 1HP regimen consists of 28 daily doses over 1 month. This combination provides a shorter, effective alternative to the traditional 9-month isoniazid regimen with higher completion rates and lower hepatotoxicity.
- Other names
- 3HP1HP
02
Targets
KatGrpoB (DNA-directed RNA polymerase subunit beta)FabI (Enoyl-acyl carrier protein reductase FabI)
Beyond the preview
Go deeper on rifapentine + isoniazid + vitamin b6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rifapentine + isoniazid + vitamin b6.